XY Capital Ltd Acquires 39,266 Shares of HUTCHMED (China) Limited Sponsored ADR $HCM

XY Capital Ltd increased its holdings in HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) by 291.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 52,757 shares of the company’s stock after buying an additional 39,266 shares during the period. XY Capital Ltd’s holdings in HUTCHMED were worth $831,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in HCM. UBS Group AG increased its stake in HUTCHMED by 112.8% during the 3rd quarter. UBS Group AG now owns 137,000 shares of the company’s stock worth $2,158,000 after acquiring an additional 72,614 shares during the period. Dimensional Fund Advisors LP lifted its position in shares of HUTCHMED by 34.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 21,721 shares of the company’s stock valued at $342,000 after acquiring an additional 5,538 shares during the period. Vanguard Personalized Indexing Management LLC grew its holdings in shares of HUTCHMED by 12.1% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 17,363 shares of the company’s stock worth $273,000 after purchasing an additional 1,873 shares in the last quarter. BNP Paribas Financial Markets increased its position in shares of HUTCHMED by 19.7% in the second quarter. BNP Paribas Financial Markets now owns 25,046 shares of the company’s stock worth $377,000 after purchasing an additional 4,116 shares during the period. Finally, Bank of America Corp DE raised its stake in HUTCHMED by 17.3% in the second quarter. Bank of America Corp DE now owns 20,582 shares of the company’s stock valued at $310,000 after purchasing an additional 3,035 shares in the last quarter. Institutional investors and hedge funds own 8.82% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. Wall Street Zen cut shares of HUTCHMED from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Bank of America dropped their target price on shares of HUTCHMED from $21.00 to $20.00 and set a “buy” rating for the company in a research report on Tuesday. Weiss Ratings reiterated a “hold (c)” rating on shares of HUTCHMED in a research report on Thursday, January 22nd. Finally, Jefferies Financial Group raised shares of HUTCHMED to a “strong-buy” rating in a research note on Monday, January 19th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $16.88.

HUTCHMED Stock Performance

Shares of NASDAQ HCM opened at $13.98 on Friday. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.96 and a quick ratio of 4.83. HUTCHMED has a 12 month low of $11.51 and a 12 month high of $19.50. The stock has a 50-day moving average price of $14.78 and a two-hundred day moving average price of $14.90.

HUTCHMED (NASDAQ:HCM) last posted its quarterly earnings results on Thursday, March 5th. The company reported $0.01 earnings per share for the quarter, missing analysts’ consensus estimates of $2.50 by ($2.49). The firm had revenue of $135.42 million for the quarter, compared to the consensus estimate of $290.50 million. As a group, equities research analysts expect that HUTCHMED will post 0.16 EPS for the current year.

About HUTCHMED

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.